TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38815953

Group type: EXPERIMENTAL
Intervention: Paired-VNS
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (sham-VNS)
Number of subjects: 108
Study: 38816042

Group type: EXPERIMENTAL
Intervention: Care bundle implementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-implementation period
Number of subjects: 0
Study: 38816040

Group type: EXPERIMENTAL
Intervention: Individualised, patient-centred rehabilitation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Biopsychosocial approach to rehabilitation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Uniform communication between caregivers
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Defined roles of interprofessional team members
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Accessible case manager
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Return to work
Number of subjects: 36
Study: 38816044

Group type: EXPERIMENTAL
Intervention: Clinical characteristics and diagnostic predictors for CAP
Number of subjects: 954
Study: 38816055

Group type: EXPERIMENTAL
Intervention: Propofol infusions
Number of subjects: 15
Study: 38816058

Group type: EXPERIMENTAL
Intervention: Parenting Wisely (PW)
Number of subjects: 60
Study: 38816232

Group type: EXPERIMENTAL
Intervention: NeoExpand (neoantigen-specific stimulation of TILs)
Number of subjects: 25
Study: 38816400

Group type: EXPERIMENTAL
Intervention: Diabetes-specific enteral nutrition formula (low glycaemic index carbohydrates, fibre (80% soluble), higher lipid content)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isocaloric isoprotein formula (control group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Diabetes-specific enteral nutrition formula (EG)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 38816482

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 300 mg per day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of EA and CBZ
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham EA plus placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adverse events related to EA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adverse events related to CBZ
Number of subjects: 120
Study: 38816554

Group type: EXPERIMENTAL
Intervention: SFD (sinus filling defect)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: HALT (hypoattenuated leaflet thickening)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: SFD
Number of subjects: 188
Study: 38816592

Group type: EXPERIMENTAL
Intervention: PrEP iT! mHealth intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 38816609

Group type: EXPERIMENTAL
Intervention: Multimodal assessment combining behavioral, neuroimaging, and electrophysiological markers
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Multimodal assessment
Number of subjects: 349
Study: 38816787

Group type: EXPERIMENTAL
Intervention: Chronic multimorbidity patterns identified through fuzzy c-means cluster analysis.
Number of subjects: 3988

Group type: EXPERIMENTAL
Intervention: Trajectories of chronic conditions over time.
Number of subjects: 3988

Group type: EXPERIMENTAL
Intervention: Stratification by sex and age group.
Number of subjects: 3988
Study: 38816810

Group type: EXPERIMENTAL
Intervention: EAdi-based parameters during SBT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: EAdi changes during SBT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Changes in EAdi and neuro-discharge per min
Number of subjects: 35
Study: 38816821

Group type: EXPERIMENTAL
Intervention: Biological age determination by DNA methylation profile
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Individual frailty assessment
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 321
Study: 38816826

Group type: EXPERIMENTAL
Intervention: Exertional desaturation during exercise testing
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Exercise testing with continuous pulse oximetry
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Personalized, risk-adapted therapy
Number of subjects: 148
Study: 38816854

Group type: EXPERIMENTAL
Intervention: Basic motor competence (BMC) training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical fitness (PF) training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Executive function (EF) training
Number of subjects: 0
Study: 38817362

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 38818022

Group type: EXPERIMENTAL
Intervention: Confident, Active and Happy Youth (CAHY) intervention, 14-session manualized physical activity-based intervention
Number of subjects: 0
Study: 38818519

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 6 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 128
Study: 38818766

Group type: EXPERIMENTAL
Intervention: Presence of underlying cardiac abnormalities
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: TR severity grades (none-trace, mild, moderate-severe)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: TV remodelling parameters (annular dilatation, tenting area)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Progressive remodelling of right-heart chambers and TV geometry
Number of subjects: 213
Study: 38818769

Group type: EXPERIMENTAL
Intervention: Task-oriented circuit training (TOCT) combined with myofascial release
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (TOCT only)
Number of subjects: 26
Study: 38818887

Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg once daily for 52 weeks
Number of subjects: 150
Study: 38818888

Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg/day
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 38818934

Group type: EXPERIMENTAL
Intervention: Ongericimab 150 mg every 2 weeks
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Ongericimab 300 mg every 4 weeks
Number of subjects: 806

Group type: COMPARATOR
Intervention: Matching placebo every 2 weeks
Number of subjects: 806

Group type: COMPARATOR
Intervention: Matching placebo every 4 weeks
Number of subjects: 806
Study: 38818936

Group type: EXPERIMENTAL
Intervention: Frequent exacerbators
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Infrequent exacerbators
Number of subjects: 1000
Study: 38819031

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 296

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 296
Study: 38819395

Group type: EXPERIMENTAL
Intervention: Donidalorsen (80 mg subcutaneously every 4 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Donidalorsen (80 mg subcutaneously every 8 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 38819408

Group type: EXPERIMENTAL
Intervention: IP nivolumab (0.5, 1, or 3 mg/kg)
Number of subjects: 17
Study: 38819500

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Green stool color
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Occasional blood in stool
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Recurrent blood in stool
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Hard stools
Number of subjects: 1052
Study: 38819614

Group type: EXPERIMENTAL
Intervention: Patients with VM and photophobia
Number of subjects: 366

Group type: COMPARATOR
Intervention: Patients without photophobia
Number of subjects: 366

Group type: COMPARATOR
Intervention: Control participants (healthy individuals)
Number of subjects: 366
Study: 38819658

Group type: EXPERIMENTAL
Intervention: 300 mg sebetralstat
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 600 mg sebetralstat
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 38819882

Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 943

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 943
Study: 38819917

Group type: EXPERIMENTAL
Intervention: Dietary supplement (PediaFlù) plus standard of care (SoC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 120
Study: 38819923

Group type: COMPARATOR
Intervention: SBIRT-A-Standard
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: SBIRT-A-Family
Number of subjects: 2300
Study: 38819983

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 38820078

Group type: EXPERIMENTAL
Intervention: Asciminib (80 mg once daily)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Investigator-selected TKIs
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Asciminib (in imatinib stratum)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Asciminib (in second-generation TKI stratum)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Second-generation TKIs
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Asciminib
Number of subjects: 405
Study: 38820246

Group type: EXPERIMENTAL
Intervention: Community-wide UTT and TB screening (Arm A)
Number of subjects: 38474

Group type: EXPERIMENTAL
Intervention: Community-wide UTT and TB screening (Arm A) among PLHIV
Number of subjects: 38474

Group type: COMPARATOR
Intervention: Standard-of-care (Arm C)
Number of subjects: 38474

Group type: COMPARATOR
Intervention: Community-wide universal HIV testing with treatment following national guidelines and TB screening (Arm B)
Number of subjects: 38474
Study: 38820294

Group type: EXPERIMENTAL
Intervention: Mild CKD group
Number of subjects: 184
Study: 38820342

Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) based on non-HLA SNPs
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: SNP rs6749137
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Pathway analysis of PRS genes
Number of subjects: 784
Study: 38820345

Group type: EXPERIMENTAL
Intervention: Diet and physical activity intervention
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control group (usual diabetes management care)
Number of subjects: 382
Study: 38820372

Group type: EXPERIMENTAL
Intervention: FUJIFILM SILVAMP TB LAM (FujiLAM)
Number of subjects: 1637
Study: 38820379

Group type: EXPERIMENTAL
Intervention: Visual-assistive apps (SuperVision+, Seeing AI, or Aira) with one-on-one training
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Telerehabilitation option for training
Number of subjects: 116

Group type: COMPARATOR
Intervention: Seeing AI app
Number of subjects: 116

Group type: COMPARATOR
Intervention: Participants from New England
Number of subjects: 116

Group type: COMPARATOR
Intervention: Participants with optical magnifier
Number of subjects: 116

Group type: COMPARATOR
Intervention: Age and cognitive scores
Number of subjects: 116
Study: 38820422

Group type: EXPERIMENTAL
Intervention: Luspatercept (1.0-1.75 mg/kg, 21-day cycles)
Number of subjects: 95
Study: 38820500

Group type: COMPARATOR
Intervention: Bendamustine plus Rituximab (BR)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Bendamustine plus Rituximab plus Bortezomib (BVR)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Rituximab (R) maintenance
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Rituximab plus Lenalidomide (LR) maintenance
Number of subjects: 373
Study: 38820520

Group type: EXPERIMENTAL
Intervention: Music only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Music + tES
Number of subjects: 30

Group type: COMPARATOR
Intervention: tES only (control condition)
Number of subjects: 30
Study: 38820549

Group type: EXPERIMENTAL
Intervention: ivonescimab plus chemotherapy
Number of subjects: 322

Group type: COMPARATOR
Intervention: placebo plus chemotherapy
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: ivonescimab
Number of subjects: 322

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 322
Study: 38820577

Group type: EXPERIMENTAL
Intervention: Ambient sensor system-derived digital biomarkers (DomoHealth SA and Emfit QS device)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: N-terminal pro b-type natriuretic peptide measurement
Number of subjects: 24
Study: 38820586

Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy (ICBT) with text messaging adjunct
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Text messaging in 3 categories: appreciating alliance, alliance building disclosures, agreement confirmation
Number of subjects: 20
Study: 38820857

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP) administered before exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: No methylphenidate (MP) administered (without MP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no ADHD)
Number of subjects: 20
Study: 38820888

Group type: EXPERIMENTAL
Intervention: IRX-2 plus durvalumab
Number of subjects: 16
Study: 38820979

Group type: EXPERIMENTAL
Intervention: Cemiplimab plus chemotherapy
Number of subjects: 327

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 327
Study: 38821083

Group type: EXPERIMENTAL
Intervention: venetoclax-obinutuzumab
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: venetoclax-obinutuzumab-ibrutinib
Number of subjects: 926

Group type: COMPARATOR
Intervention: chemoimmunotherapy
Number of subjects: 926

Group type: COMPARATOR
Intervention: venetoclax-rituximab
Number of subjects: 926
Study: 38821086

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of major adverse cardiovascular events among survivors
Number of subjects: 9602

Group type: COMPARATOR
Intervention: Cumulative incidence of major adverse cardiovascular events among community controls
Number of subjects: 9602

Group type: EXPERIMENTAL
Intervention: Cumulative burden of major adverse cardiovascular events in survivors
Number of subjects: 9602

Group type: COMPARATOR
Intervention: Cumulative burden of major adverse cardiovascular events in community controls
Number of subjects: 9602

Group type: EXPERIMENTAL
Intervention: One non-major adverse cardiovascular condition
Number of subjects: 9602

Group type: EXPERIMENTAL
Intervention: Two non-major adverse cardiovascular conditions
Number of subjects: 9602

Group type: EXPERIMENTAL
Intervention: Three non-major adverse cardiovascular conditions
Number of subjects: 9602

Group type: EXPERIMENTAL
Intervention: Grade 1 arrhythmias
Number of subjects: 9602

Group type: EXPERIMENTAL
Intervention: Grade 2 left ventricular systolic dysfunction
Number of subjects: 9602

Group type: EXPERIMENTAL
Intervention: Grade 2 valvular disorders
Number of subjects: 9602
Study: 38821260

Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard GL diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet and calorie restriction (CR)
Number of subjects: 100
Study: 38821261

Group type: EXPERIMENTAL
Intervention: Virtual multiteam systems (VMTS) for caregiver-implemented intervention
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cross-site data collection activities
Number of subjects: 240
Study: 38821453

Group type: EXPERIMENTAL
Intervention: Early aortic valve replacement (surgical or transcatheter)
Number of subjects: 2844

Group type: COMPARATOR
Intervention: Watchful waiting (control group)
Number of subjects: 2844
Study: 38821545

Group type: EXPERIMENTAL
Intervention: 'My Bowels on Track' smartphone application with weekly/biweekly electronic patient-reported outcomes (PROs) and alerting system.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 'My Bowels on Track' smartphone application with alerting system.
Number of subjects: 40
Study: 38821574

Group type: EXPERIMENTAL
Intervention: Machine learning-guided approach
Number of subjects: 7584

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 7584
Study: 38821658

Group type: EXPERIMENTAL
Intervention: 660 nm diode laser
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 970 nm diode laser
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 445 nm diode laser
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no laser treatment)
Number of subjects: 9
Study: 38821718

Group type: EXPERIMENTAL
Intervention: Nivolumab plus relatlimab
Number of subjects: 50
Study: 38821761

Group type: EXPERIMENTAL
Intervention: Contemporary management of acute myocardial infarction
Number of subjects: 19000

Group type: EXPERIMENTAL
Intervention: Follow-up period linked with the French national health database
Number of subjects: 19000

Group type: EXPERIMENTAL
Intervention: Assessment of medical care costs for index hospitalization and follow-up
Number of subjects: 19000

Group type: EXPERIMENTAL
Intervention: Investigating determinants of prognosis (including periodontal disease and sleep-disordered breathing)
Number of subjects: 19000
Study: 38821945

Group type: EXPERIMENTAL
Intervention: Robotic distal gastrectomy (RDG)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 300
Study: 38821996

Group type: EXPERIMENTAL
Intervention: Tattooed skin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Permanent tattoos older than 1 year
Number of subjects: 16
Study: 38822042

Group type: EXPERIMENTAL
Intervention: Impaired RAP variation (defined as end-expiratory RAP - end-inspiratory RAP ≤ 2 mm Hg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Preserved RAP variation
Number of subjects: 75
Study: 38822190

Group type: EXPERIMENTAL
Intervention: Presence of patent foramen ovale (PFO)
Number of subjects: 450
Study: 38822245

Group type: EXPERIMENTAL
Intervention: Juggling three times a week during four weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: No juggling (control phase) for four weeks
Number of subjects: 26
Study: 38822300

Group type: EXPERIMENTAL
Intervention: Daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 48 weeks
Number of subjects: 130
Study: 38822324

Group type: EXPERIMENTAL
Intervention: Digital cognitive stimulation using HappyNeuron PRESCO software App on tablets, with three 20-minute sessions (first supervised by a neuropsychologist).
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Digital cognitive stimulation sessions.
Number of subjects: 55
Study: 38822342

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 0
Study: 38822391

Group type: EXPERIMENTAL
Intervention: Guanfacine (sympatholytic), 6 weeks treatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (diuretic), 6 weeks treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 38822389

Group type: EXPERIMENTAL
Intervention: Handheld fluorescence imaging device with 5-aminolevulinic acid (5-ALA) administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Handheld fluorescence imaging device
Number of subjects: 0
Study: 38822758

Group type: EXPERIMENTAL
Intervention: Taletrectinib
Number of subjects: 173
Study: 38822858

Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lower urinary tract dysfunction (LUTD)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Holding maneuvers
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Urinary urgency
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Daytime urinary incontinence
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Enuresis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dysfunctional Voiding and Incontinence Scoring System (DVISS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LUTS score
Number of subjects: 45
Study: 38822943

Group type: COMPARATOR
Intervention: IV CM-101 2.5 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: SC CM-101 5.0 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: IV CM-101 (0.75 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10.0 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IV CM-101
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SC CM-101
Number of subjects: 100
Study: 38822948

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL, 595 nm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IPL with Delicate Pulse Light (DPL, 500-600 nm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IPL with M22 590 (590-1200 nm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IPL with M22 vascular filter (530-650 nm and 900-1200 nm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All four laser treatments
Number of subjects: 60

Group type: COMPARATOR
Intervention: M22 vascular group
Number of subjects: 60
Study: 38823034

Group type: EXPERIMENTAL
Intervention: Cabozantinib (40 mg p.o. daily on days 1-21 of a 21-day cycle) and Pembrolizumab (200 mg i.v. on day 1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cabozantinib and Pembrolizumab
Number of subjects: 27
Study: 38823398

Group type: EXPERIMENTAL
Intervention: Durvalumab plus gemcitabine-cisplatin
Number of subjects: 914

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine-cisplatin
Number of subjects: 914
Study: 38823410

Group type: EXPERIMENTAL
Intervention: BL-B01D1 at 3·0 mg/kg on days 1 and 8 every 3 weeks
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: BL-B01D1 at 6·0 mg/kg on day 1 every 3 weeks
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: BL-B01D1
Number of subjects: 195
Study: 38823511

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 260

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 260
Study: 38823603

Group type: EXPERIMENTAL
Intervention: High fear of movement (FOM) as measured by the Tampa Scale of Kinesiophobia-11
Number of subjects: 135

Group type: COMPARATOR
Intervention: Low fear of movement (FOM) as measured by the Tampa Scale of Kinesiophobia-11
Number of subjects: 135
Study: 38823849

Group type: EXPERIMENTAL
Intervention: ICC hummus meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: RCC hummus meal
Number of subjects: 15
Study: 38824242

Group type: EXPERIMENTAL
Intervention: Fruquintinib plus paclitaxel
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 703